中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2011年
7期
60-62
,共3页
王峰%王华启%楚荷莹%王书钧%张国俊
王峰%王華啟%楚荷瑩%王書鈞%張國俊
왕봉%왕화계%초하형%왕서균%장국준
紫杉醇脂质体%非小细胞肺癌%顺铂
紫杉醇脂質體%非小細胞肺癌%順鉑
자삼순지질체%비소세포폐암%순박
Paclitaxel liposomal%Non-small cell lung cancer%Cisplatin
目的 比较国产注射用紫杉醇脂质体+顺铂与紫杉醇+顺铂治疗非小细胞肺癌的临床疗效和安全性.方法 采用随机、对照的方法进行研究,非小细胞肺癌130例分为试验组和对照组两组,两组各65例.试验组给予注射用紫杉醇脂质体135 mg/m2,第1天+顺铂30 mg/m2,第1、2、3天,每3周为1个周期;对照组给予注射用紫杉醇135 mg/m2,第1天+顺铂30 mg/m2,第1、2、3天,每3周为1个周期.结果 共有120例患者可评价疗效和不良反应,两组各60例.试验组总有效率62.7%,对照组总有效率50.0%,但差异无统计学意义(P>0.05).主要不良反应为血液学毒性,以白细胞减少最明显,但差异无统计学意义(P>0.05).其他非血液学毒性不良反应方面,皮疹、恶心呕吐和肌肉痛,试验组发生率低于对照组,差异有统计学意义(P<0.05).结论 国产注射用紫杉醇脂质体联合顺铂治疗非小细胞肺癌和传统紫杉醇效果相当,但其溶媒所产生的皮疹、恶心呕吐和肌肉痛等不良反应较传统紫杉醇少.
目的 比較國產註射用紫杉醇脂質體+順鉑與紫杉醇+順鉑治療非小細胞肺癌的臨床療效和安全性.方法 採用隨機、對照的方法進行研究,非小細胞肺癌130例分為試驗組和對照組兩組,兩組各65例.試驗組給予註射用紫杉醇脂質體135 mg/m2,第1天+順鉑30 mg/m2,第1、2、3天,每3週為1箇週期;對照組給予註射用紫杉醇135 mg/m2,第1天+順鉑30 mg/m2,第1、2、3天,每3週為1箇週期.結果 共有120例患者可評價療效和不良反應,兩組各60例.試驗組總有效率62.7%,對照組總有效率50.0%,但差異無統計學意義(P>0.05).主要不良反應為血液學毒性,以白細胞減少最明顯,但差異無統計學意義(P>0.05).其他非血液學毒性不良反應方麵,皮疹、噁心嘔吐和肌肉痛,試驗組髮生率低于對照組,差異有統計學意義(P<0.05).結論 國產註射用紫杉醇脂質體聯閤順鉑治療非小細胞肺癌和傳統紫杉醇效果相噹,但其溶媒所產生的皮疹、噁心嘔吐和肌肉痛等不良反應較傳統紫杉醇少.
목적 비교국산주사용자삼순지질체+순박여자삼순+순박치료비소세포폐암적림상료효화안전성.방법 채용수궤、대조적방법진행연구,비소세포폐암130례분위시험조화대조조량조,량조각65례.시험조급여주사용자삼순지질체135 mg/m2,제1천+순박30 mg/m2,제1、2、3천,매3주위1개주기;대조조급여주사용자삼순135 mg/m2,제1천+순박30 mg/m2,제1、2、3천,매3주위1개주기.결과 공유120례환자가평개료효화불량반응,량조각60례.시험조총유효솔62.7%,대조조총유효솔50.0%,단차이무통계학의의(P>0.05).주요불량반응위혈액학독성,이백세포감소최명현,단차이무통계학의의(P>0.05).기타비혈액학독성불량반응방면,피진、악심구토화기육통,시험조발생솔저우대조조,차이유통계학의의(P<0.05).결론 국산주사용자삼순지질체연합순박치료비소세포폐암화전통자삼순효과상당,단기용매소산생적피진、악심구토화기육통등불량반응교전통자삼순소.
Objective To analyze the effects and side effects of paclitaxel liposomal plus cisplatin formula on non-small cell lung cancer(NSCLC),compared with traditional paclitaxel plus cisplatin. Methods One hundred and thirty cases of NSCLC were randomly divided into test group (65 cases) given paclitaxel liposomal at 135 mg/m2 each session, and control group(65 cases) given traditional paclitaxel at 135 mg/m2 each session.Both groups received these regimens combined with cisplatin at 30 mg/m2 d1,d2,d3/every cycle,every 3 weeks cycle. Results Of all the 130 cases,120 cases were eligible for the analysis of side effects and the overall response rate. Sixty cases in each group.The overall response rate were 62.7% in the test group and 50.0% in the control group. There was no significant difference between the two groups(P>0.05). The main adverse reactions to the toxicity of hematology is the reducing of the white blood cell,but there was no significant difference between the two groups. Non-hematologic toxic side effects were rash,nausea and vomiting,muscle pain,the incidence was significantly lower in the test group than that in the control group(P<0.05). Conclusions Paclitaxel liposomal combined with cisplatin in the treatment of NSCLC, being similarily effective as paclitaxel, can significantly lower the incidence of rash,nausea and vomiting,muscle pain.
